What does monosomy 7 (loss of one copy of chromosome 7) in 52% of cells indicate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Monosomy 7 at 52% Indicates High-Risk Myeloid Neoplasm

Monosomy 7 (loss of one copy of chromosome 7) detected in 52% of cells represents a clonal chromosomal abnormality that defines a high-risk myeloid neoplasm, most commonly myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), and requires immediate hematologic workup and aggressive management including consideration for allogeneic stem cell transplantation.

What This Finding Means

The 52% frequency indicates this is a clonal abnormality (not constitutional), as normal bone marrow cells retain two copies of chromosome 7. This percentage exceeds the threshold for defining a neoplastic clone and establishes the presence of a myeloid malignancy 1.

Disease Associations

Monosomy 7 is:

  • The most common clonal chromosomal change in MDS and second most frequent in AML 2
  • An MDS-defining cytogenetic abnormality when present with appropriate morphologic features 1
  • Associated with abnormal erythroid, megakaryocyte, and myeloid differentiation 2

Critical exception per NCCN guidelines: Patients with monosomy 7 in lower-risk MDS by other criteria should be treated in the higher prognostic risk category 3. This overrides other risk stratification systems.

Prognostic Implications

Poor Prognosis Across All Age Groups

Monosomy 7 defines an adverse prognostic group across all patient populations 2, 4:

  • Worse outcomes than del(7q): Patients with complete monosomy 7 have lower complete remission rates (47.6% vs 70%) and higher death rates (62% vs 40%) compared to those with 7q deletion alone 4
  • Median overall survival: 32 months for monosomy 7 versus 43 months for del(7q) and 50 months for normal chromosome 7 (p=0.001) 4
  • Pediatric cases: In children, monosomy 7 represents a myeloproliferative disorder with high risk of progression to AML, typically resistant to chemotherapy 5

Mechanism of Poor Prognosis

The loss results in haploinsufficiency of multiple genes on chromosome 7, likely involving tumor suppressor genes 2, 6. This leads to:

  • Increased cell proliferation and apoptosis
  • Failure of normal hematopoietic maturation
  • Resistance to standard chemotherapy 5, 2

Required Workup

Based on ACMG guidelines 1, the diagnostic approach should include:

  1. G-banded chromosome analysis (if not already performed) - recommended first-line test

  2. Complete MDS FISH panel to identify additional abnormalities:

    • -5/5q- probes
    • TP53 (17p13.1) probe - critical for identifying biallelic TP53 inactivation
    • Trisomy 8 probe
    • 20q deletion probe
  3. Chromosomal microarray (CMA) if karyotype incomplete or to detect copy-neutral loss of heterozygosity (CN-LOH), particularly involving TP53 1

  4. Next-generation sequencing (NGS) for somatic variants, especially:

    • TP53 mutations - defines MDS with biallelic TP53 inactivation when combined with TP53 deletion/CN-LOH 1, 3
    • Other recurrent MDS-associated mutations (SF3B1, ASXL1, etc.)

Critical Pitfall to Avoid

Do not confuse monosomy 7 in Philadelphia chromosome-negative cells in CML patients (which may be benign and transient during TKI therapy 7) with monosomy 7 in primary myeloid neoplasms. The clinical context matters - this finding in a CML patient on TKI therapy has different implications than in de novo MDS/AML.

Management Approach

Higher-Risk Category Treatment

Per NCCN guidelines 3, monosomy 7 mandates higher-risk management:

Primary treatment options:

  • Allogeneic hematopoietic cell transplantation (HCT) - the only potentially curative option and should be considered for all eligible patients 3, 5
  • Hypomethylating agents (HMAs): Azacitidine or decitabine (including oral decitabine/cedazuridine) with or without venetoclax 3
  • Clinical trial enrollment - strongly encouraged given poor outcomes with standard therapy

Do NOT use lenalidomide - even in lower-risk appearing MDS, as monosomy 7 is specifically listed as an exception requiring higher-risk treatment 3

Transplant Considerations

Allogeneic HCT provides the best chance for durable remission, though outcomes remain challenging:

  • Two-year leukemia-free survival post-HCT: approximately 30-48% depending on additional cytogenetic abnormalities 8
  • Better outcomes when monosomy 7 occurs without monosomal karyotype, -5/5q-, 17p abnormalities, or inv(3) 8
  • Consider matched sibling, unrelated, haploidentical, or cord blood donors with standard or reduced-intensity conditioning 3

Monitoring Strategy

Establish baseline FISH for the monosomy 7 clone to enable future monitoring of measurable residual disease 1. This allows tracking of treatment response and early detection of relapse.

Additional Cytogenetic Context Matters

The presence of concomitant abnormalities significantly impacts prognosis even after transplant 8:

  • Monosomy 7 alone or with complex karyotype (without monosomal karyotype): 2-year LFS ~48%
  • With monosomal karyotype: 2-year LFS ~36%
  • With -5/5q-: 2-year LFS ~28%
  • With 17p abnormalities: 2-year LFS ~19%
  • With inv(3): 2-year LFS ~17%

This underscores why comprehensive cytogenetic and molecular characterization is essential for accurate risk stratification and treatment planning.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.